Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a fully integrated commercial biotechnology company, announced that its management team will participate in two upcoming investor conferences in May 2026: the RBC Capital Markets Global Healthcare Conference on May 19 in New York and A.G.P.’s Annual Virtual Healthcare Conference on May 20. The company’s participation underscores its commitment to engaging with the investment community as it advances its pipeline of central nervous system (CNS) and immunology treatments.
Tonix Pharmaceuticals is focused on areas of high unmet medical need. Its recently approved flagship medicine, TONMYA™ (cyclobenzaprine HCl sublingual tablets 2.8mg), represents the first new treatment for fibromyalgia in more than 15 years. The company’s CNS commercial infrastructure supports its marketed products, including acute migraine treatments Zembrace® SymTouch® and Tosymra®. Tonix is also exploring the potential of TONMYA in Phase 2 clinical trials for major depressive disorder and acute stress disorder.
Beyond its commercial portfolio, Tonix’s CNS pipeline includes TNX-2900, a Phase 2-ready candidate for Prader-Willi syndrome, a rare disease with no approved therapies. In immunology, the company is advancing monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for preventing kidney transplant rejection. These investigational products highlight Tonix’s commitment to addressing critical healthcare challenges.
The investor conferences provide a platform for Tonix to showcase its progress and strategic vision. The RBC Capital Markets Global Healthcare Conference is a premier event for healthcare investors, while A.G.P.’s Virtual Healthcare Conference offers a digital venue for engagement. Tonix’s participation is expected to generate interest among analysts and investors seeking exposure to innovative biotechnology companies.
For more information about Tonix Pharmaceuticals and its pipeline, visit the company’s newsroom at https://ibn.fm/TNXP. Details of the press release are available at https://ibn.fm/ZZpG2.
